What is Kardium?
Headquartered in Burnaby, British Columbia, and established in 2007, Kardium specializes in the engineering of high-precision medical devices. The company is primarily focused on the development of innovative mapping and ablation technologies that provide clinicians with enhanced diagnostic and therapeutic capabilities for treating atrial fibrillation. Through its commitment to rigorous research and development, Kardium has emerged as a critical player in the electrophysiology market, bridging the gap between complex cardiac diagnostics and effective patient outcomes. The firm's operational maturity is evidenced by its sustained ability to attract institutional capital, positioning it as a high-growth entity within the global medical device landscape.
How much funding has Kardium raised?
Kardium has raised a total of $474.9M across 5 funding rounds:
Private Equity
$867K
Other Financing Round
$115M
Grant
$5M
Other Financing Round
$104M
Series D
$250M
Private Equity (2010): $867K, investors not publicly disclosed
Other Financing Round (2021): $115M led by T. Rowe Price Associates and Fidelity Management & Research Company
Grant (2022): $5M supported by Government of Canada
Other Financing Round (2024): $104M featuring Durable Capital Partners, T. Rowe Price, and Fidelity Management Services
Series D (2025): $250M backed by T. Rowe Price, Fidelity, and Durable Capital Partners
Key Investors in Kardium
T. Rowe Price
A global investment management firm that provides equity and fixed income mutual funds to institutional and individual clients, known for its long-term investment horizon.
Fidelity
A diversified financial services giant offering comprehensive wealth management and advisory solutions, frequently participating in large-scale private and public market financings.
Durable Capital Partners
An investment adviser focused on identifying and supporting high-potential compounders across both public and private equity markets.
What's next for Kardium?
With the successful completion of this major strategic investment, Kardium is well-positioned to accelerate its clinical trial programs and expand its commercial footprint. The company's strategic roadmap likely involves scaling manufacturing capabilities to meet the increasing demand for its proprietary ablation systems while simultaneously pursuing regulatory milestones in key international markets. As Kardium transitions into this next phase of enterprise-level scaling, the focus will remain on enhancing the efficacy of its medical technology suite, thereby reinforcing its competitive advantage in the treatment of cardiac arrhythmias. The continued support from top-tier institutional investors provides the necessary runway to sustain long-term innovation and market penetration.
See full Kardium company page
